Introduction
Head-and-neck cancer refers to a group of the malignant tumors arising at a variety of sites in the upper aerodigestive tract, the most commonly in the oral cavity, the oropharynx, the hypopharynx and the larynx. The squamous cell carcinoma (SCC) is the predominant histological type (about 90%) and the sixth leading neoplasm by incidence worldwide with more than 650,000 new cases diagnosed per year [1] . At the time of diagnosis most patients have the locally advanced disease and lymph node metastases [2] . Despite advances in therapy during past decade, Peer review under the responsibility of the Lithuanian University of Health Sciences.
prognosis and long-term survival of patients with locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC) are poor. Combined chemoradiotherapy, including monoclonal antibodies, represents state-of-the art treatment for LAHNSCC. Cetuximab (CTX) is a monoclonal antibody targeted to epidermal growth factor receptor (EGFR). It has been approved for use in combination with radiation during treatment of primary locoregionally advanced (stage III to IVB) HNSCC or as monotherapy for the treatment of recurrent or metastatic HNSCC after the failure of platinum-based chemotherapy, and also in combination with platinum/5-fluorouracil for the treatment of the recurrent or metastatic disease. Treatment with this anti-EGFR antibody is expensive and absolute difference in median overall survival at 3 years in LAHNSCC patients is 19.7 months (29.3 months in RT only group vs. 49 months in RT/CTX group). This corresponds to 10% absolute benefit in median overall survival in the RT/CTX group [3] . The majority of patients with LAHNSCC do not take advantage either because they have been cured by RT alone or are unresponsive on the long term. Hence, it is desirable to early predict the efficacy of the treatment with CTX/RT to better select good responders.
2.
Case report FDG uptake in the tumor and the metastatic lymph node (Fig. 1) . The main parameters of both 18 FDG-PET/CT scans are summarized in Table 1 . 
Specific toxicity of CTX was observed as the grade III maculopapular skin rash and required the topical application of metronidazole cream and oral intake of doxycycline 100 mg 2 times a day.
A complete response to the treatment was determined by 18 FDG-PET/CT scan 3 months later past RT on September 17, 2009. Further monitoring confirmed the complete remission. After nearly five years, the patient remains free of disease progression.
Discussion

18
FDG-PET is a molecular imaging technique that exploits preferential utilization of aerobic glycolysis by tumor cells.
FDG-PET has been used in cancer patients since the 1980s and is now a widely used clinical imaging tool in oncology. Significant reduction in 18 FDG uptake identified by PET can indicate modulation of EGFR function or other mechanisms involved in the regulation of glucose metabolism in cancer cells. Preclinical studies using breast cancer cell lines showed marked inhibition of glucose uptake and retention over a period of hours following treatment with the anti-EGFR antibody cetuximab [4] .
Aerobic glycolysis is a defining feature of cancer and is characterized by increased metabolism of glucose to lactate in the presence of sufficient oxygen [5] . The rate of adenosine triphosphate (ATP) generation becomes greater if respiration occurs through glycolysis. This enables cancer cells to gain competitive advantage for shared energy resources such as glucose etc. Tumors that take up more glucose than surrounding tissues can be noninvasively visualized in cancer patients by 18 FDG-PET. Hypoxia is another key feature of many types of tumors [6] . Hypoxic cells often use enhanced glycolysis to maintain production of energy.
18 FDG uptake might indicate a state of hypoxia [7] , because it is related to a higher expression of glucose transporter GLUT-4 in hypoxic cells [8] , which is responsible for the internalization and entrapment of 18 FDG into the cell. However, 18 FDG uptake should not be considered as a surrogate marker for hypoxia [9] .
Su et al. demonstrated that reduction of hypoxia by CTX was observed only in tumor cells highly sensitive to this treatment [10] .
Most of adaptations to tumor hypoxia -including the shifting of metabolism toward glycolysis -are commonly orchestrated by the hypoxia inducible factors (HIFs) [11] . Li et al. observed that CTX decreases the HIF-1a level and concluded that downregulation of HIF-1a is required to maximize therapeutic response of cancer cells to CTX [12] .
Lu et al. demonstrated that, following EGFR-targeted therapy, HIF-1 selectively decreased in responsive cell lines only [13] .
Sequential imaging during treatment by means of 18 FDG-PET reveals glucose uptake patterns that might aid predicting treatment effectiveness [14] . But there is still no clinical data that shows possible predictive value for early evaluation of tumor response to CTX by means of PET-CT. Regarding the predictive value of 18 FDG-PET in early prediction of clinical response to anti-EGFR therapy there is one study with panitumumab. A chemotherapy-refractory patient necessitated a quick identification of an effective agent. The authors used the 18 FDG-PET scan 48 h after the initial dose of panitumumab to determine pharmacodynamic response to the antibody. In this case report, the initial 46% reduction of SUVmax for target lesions correlated well with partial response past 8 weeks [15] . By analogy, we observed in the present case a 71.7% reduction of SUVmax on 18 FDG-PET scan 10 days after CTX loading dose.
Conclusions
Prediction of tumor response to the treatment is burning topic in oncology. Despite the initial optimism, it should be noted that results of clinical trials show the limited effectiveness of targeted therapy. Treatment with CTX is very expensive. In order to reduce health costs, it would be appropriate to administer treatment to the patients with HNSCC, which may benefit from this treatment and early predict the likely effectiveness of the therapy. Experimental studies show that there are specific metabolic changes in tumors, in particular the phenomenon of glycolysis, which is associated with hypoxia in tumors and could be controlled through the stimulation of EGFR-dependent and independent mechanisms. Perhaps the most important changes in the metabolism of tumor cells are regulated by HIF-1a. Studies have shown that down-regulation of HIF-1a is necessary to ensure the effectiveness of CTX and is associated with decreased glycolysis and tumor hypoxia. Studies have shown that hypoxia decreases in tumor cell lines that are very sensitive to CTX. Since glycolysis mechanism is closely related to HIF-1a and could be evaluated by changes in TLG measured by 18 FDG-PET, we assume that 18 FDG-PET examination could be used as a measure to early predict the efficiency of CTX.
In this article we present our experience in evaluating response of LAHNSCC to the treatment with CTX. Response to the treatment was assessed by repeated examination with 18 FDG-PET/CT. The reported clinical case indicates that SCC of hypopharynx was very sensitive to CTX and this was reflected by sharp decrease of 18 FDG-PET parameters during the first FDG-PET examination could predict the efficacy of CTX and, hence, lead to early selection of good responders.
